Glaukos Corporation (NYSE:GKOS - Free Report) - Zacks Research raised their Q1 2028 earnings estimates for shares of Glaukos in a research note issued on Wednesday, November 18th. Zacks Research analyst Team now expects that the medical instruments supplier will post earnings of $0.27 per share for the quarter, up from their previous forecast of $0.18. Zacks Research currently has a "Strong-Buy" rating on the stock. The consensus estimate for Glaukos' current full-year earnings is $0.50 per share. Zacks Research also issued estimates for Glaukos' Q2 2028 earnings at $0.45 EPS.
Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.57. The firm had revenue of $211.03 million for the quarter, compared to the consensus estimate of $168.04 million. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. The firm's quarterly revenue was up 58.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.16) earnings per share.
GKOS has been the topic of several other reports. JPMorgan Chase & Co. increased their target price on shares of Glaukos from $200.00 to $240.00 and gave the stock an "overweight" rating in a research note on Thursday, October 29th. Weiss Ratings restated a "sell (d-)" rating on shares of Glaukos in a research note on Thursday, October 15th. Citigroup upped their price target on Glaukos from $225.00 to $247.00 and gave the stock a "buy" rating in a report on Thursday, October 29th. UBS Group assumed coverage on Glaukos in a report on Tuesday, July 28th. They issued a "neutral" rating and a $150.00 price target for the company. Finally, BTIG Research increased their price target on Glaukos from $234.00 to $252.00 and gave the stock a "buy" rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $218.00.
Check Out Our Latest Analysis on Glaukos
Glaukos Stock Down 4.4%
GKOS opened at $232.59 on Thursday. Glaukos has a fifty-two week low of $91.83 and a fifty-two week high of $255.18. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.09 and a current ratio of 4.57. The company has a fifty day moving average of $188.17 and a two-hundred day moving average of $148.89. The stock has a market capitalization of $13.77 billion, a price-to-earnings ratio of -79.11 and a beta of 0.68.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. EWA LLC acquired a new stake in Glaukos during the 3rd quarter worth $218,000. Algert Global LLC raised its position in shares of Glaukos by 43.7% in the third quarter. Algert Global LLC now owns 44,361 shares of the medical instruments supplier's stock valued at $7,284,000 after buying an additional 13,490 shares during the last quarter. Castleark Management LLC acquired a new stake in shares of Glaukos in the third quarter valued at about $7,812,000. Virtu Financial LLC purchased a new position in shares of Glaukos in the third quarter worth about $338,000. Finally, Allworth Financial LP lifted its stake in shares of Glaukos by 27.3% in the third quarter. Allworth Financial LP now owns 252 shares of the medical instruments supplier's stock worth $41,000 after buying an additional 54 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.
Insider Buying and Selling at Glaukos
In other Glaukos news, Director Gilbert Kliman sold 2,500 shares of the stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $253.00, for a total transaction of $632,500.00. Following the transaction, the director directly owned 37,406 shares of the company's stock, valued at $9,463,718. This trade represents a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Joseph E. Gilliam sold 44,917 shares of Glaukos stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $246.32, for a total transaction of $11,063,955.44. Following the completion of the sale, the chief operating officer owned 71,602 shares in the company, valued at approximately $17,637,004.64. This trade represents a 38.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 48,278 shares of company stock worth $11,911,705. Insiders own 5.90% of the company's stock.
Glaukos Company Profile
(
Get Free Report)
Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Glaukos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.
While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.